nach oben

Erschienen in:

21.10.2022 | Stammzell-Transplantation | Zertifizierte Fortbildung Neurologie

Reboot des Immunsystems

Stammzelltransplantation bei Multipler Sklerose - wo stehen wir?

verfasst von: Prof. Dr. med. Christoph Heesen, Dr. med. Dr. rer. biol. hum. Max Kaufmann, Dr. med. Dietlinde Janson, Dr. med. Vivien Häußler, Prof. Dr. med. Nicolaus Kröger, Prof. Dr. med. Manuel A. Friese

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Auszug

Die autologe hämatopoetische Stammzelltransplantation wird seit Mitte der 1990er-Jahre als Behandlungsmöglichkeit bei Multipler Sklerose klinisch untersucht und inzwischen in einigen spezialisierten Zentren auch in der Versorgung außerhalb von Studien eingesetzt. Sie ist eine wertvolle Therapie für aggressive Verläufe der Multiplen Sklerose, insbesondere bei Versagen hochwirksamer Therapien bei persistierenden Schüben und MRT-Aktivität. …

Kappos L et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132-40

Wolinsky JS et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19(12):998-1009

Willison AG et al. The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. J Neurol. 2022;269(7):3937-58

Snowden JA et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022

Hemmer B et al. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen: Deutsche Gesellschaft für Neurologie; 2021 (www.dgn.org/leitlinien)

Muraro PA et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13(7):391-405

Miller AE et al. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society. JAMA Neurol. 2021;78(2):241-6

Sharrack B et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT ADWP and the JACIE EBMT and ISCT. Bone Marrow Transplant. 2020;55(2):283-306

Menon S et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(11):1192-8

10.

Attfield KE et al. The immunology of multiple sclerosis. Nat Rev Immunol. 2022 May 4. doi: 10.1038/s41577-022-00718-z.

11.

Lanz TV et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321-7

12.

Bjornevik K et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301

13.

Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25-36

14.

Cencioni MT et al. Immune reconstitution following autologous hematopoietic stem cell transplantation for multiple sclerosis: a review on behalf of the EBMT autoimmune diseases working party. Front Immunol. 2021;12:813957

15.

Burt RK et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321(2):165-74

16.

Zhang P, Liu B. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis. Bone Marrow Transplant. 2020;55(10):1928-34

17.

Sormani MP et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. Neurology. 2017;88(22):2115-22

18.

Bose G et al. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. Mult Scler. 2021;27(2):167-73

19.

Atkins HL et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388(10044):576-85

20.

Nash RA et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842-52

21.

Casanova B et al. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurol Sci. 2017;38(7):1213-21

22.

Alping P et al. Safety of Alemtuzumab and autologous hematopoietic stem cell transplantation compared to noninduction therapies for multiple sclerosis. Neurology. 2021;96(11):e1574-e84

23.

Zhukovsky C et al. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study. J Neurol Neurosurg Psychiatry. 2021;92(2):189-94

24.

Boffa G et al. Long-Term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2021 Jan 20; doi: 10.1212/WNL.0000000000011461

25.

Burt RK et al. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. J Neurol. 2022;269(5):2513-26

26.

Häußler V et al. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis. Ann Clin Transl Neurol. 2021;8(6):1269-78

27.

Muraro PA et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol. 2017;74(4):459-69

28.

Mariottini A et al. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis. Eur J Neurol. 2022;29(6):1708-18

29.

Mariottini A. HSCT outcome in progressive MS: is there evidence of benefit and acceptable risk? ECTRIMS focused workshop, Online 10.-11.3.2022

30.

Das J et al. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis. Mult Scler. 2021;27(8):1198-204

31.

Nicholas RS et al. Autologous hematopoietic stem cell transplantation in active multiple sclerosis: a real-world case series. Neurology. 2021;97(9):e890-e901

32.

Chatterton S et al. Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis. Mult Scler. 2021;27(13):2112-5

33.

Kobelt G et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123-36

34.

Tappenden P et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant. 2010;45(6):1014-21

Titel: Reboot des Immunsystems
Stammzelltransplantation bei Multipler Sklerose - wo stehen wir?
verfasst von: Prof. Dr. med. Christoph Heesen
Dr. med. Dr. rer. biol. hum. Max Kaufmann
Dr. med. Dietlinde Janson
Dr. med. Vivien Häußler
Prof. Dr. med. Nicolaus Kröger
Prof. Dr. med. Manuel A. Friese
Publikationsdatum: 21.10.2022
Verlag: Springer Medizin
Schlagwörter: Stammzell-Transplantation
Stammzell-Transplantation
Multiple Sklerose
Stammzell-Transplantation
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 10/2022
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-022-3002-0

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Alphasynuclein-Antikörper und Parkinson: Scheitern und Resthoffnungen

Endlich eine Phase-III-Studie für Rituximab

Fortschritte in der Diagnostik und bald auch bei der Therapie

Mehr Diagnosesicherheit durch neue MRT-Marker

Ein Medikament gegen Adipositas?

Antihypertensiva: Absage an die abendliche Einnahme